Assessment of Sexual Health in Aging Men in Europe: Development and Validation of the European Male Ageing Study Sexual Function Questionnaire by O'Connor, Daryl B et al.
O’Connor, Daryl B and Corona, Giovanni and Forti, Gianni and Tajar, Ab-
delouahid and Lee, David M and Finn, Joseph D and Bartfai, Gyorgy and
Boonen, Steven and Casanueva, Felipe F and Giwercman, Aleksander and
Huhtaniemi, Ilpo T and Kula, Krzysztof and O’Neill, Terence W and Pendle-
ton, Neil and Punab, Margus and Silman, Alan J and Vanderschueren, Dirk
and Wu, Frederick CW (2008)Assessment of Sexual Health in Aging Men
in Europe: Development and Validation of the European Male Ageing Study
Sexual Function Questionnaire. Journal of Sexual Medicine, 5 (6). pp. 1374-
1385. ISSN 1743-6095
Downloaded from: http://e-space.mmu.ac.uk/622739/
Version: Accepted Version
Publisher: Elsevier
DOI: https://doi.org/10.1111/j.1743-6109.2008.00781.x
Usage rights: Creative Commons: Attribution-Noncommercial-No Deriva-
tive Works 3.0
Please cite the published version
https://e-space.mmu.ac.uk
ORIGINAL RESEARCH—OUTCOMES ASSESSMENT
Assessment of Sexual Health in Aging Men in Europe:
Development and Validation of the European Male Ageing Study
Sexual Function Questionnaire
Daryl B. O’Connor, PhD,* Giovanni Corona,† Gianni Forti, MD,† Abdelouahid Tajar, PhD,‡
David M. Lee, PhD,‡ Joseph D. Finn, BSc,‡ Gyorgy Bartfai, MD,§ Steven Boonen, MD,¶
Felipe F. Casanueva, MD, PhD,** Aleksander Giwercman, MD, PhD,†† Ilpo T. Huhtaniemi, MD, PhD,‡‡
Krzysztof Kula, MD, PhD,§§ Terence W. O’Neill, MD,‡ Neil Pendleton, MD,¶¶
Margus Punab, MD, PhD,*** Alan J. Silman, MD,‡ Dirk Vanderschueren, MD, PhD,¶
Frederick C.W. Wu, MD,††† and the European Male Ageing Study group1
*Institute of Psychological Sciences, University of Leeds, Leeds, UK; †Andrology Unit, Department of Clinical
Physiopathology, University of Florence, Florence, Italy; ‡ARC Epidemiology Unit, The University of Manchester,
Manchester, UK; §Department of Obstetrics, Gynaecology and Andrology, Albert Szent-Gyorgy Medical University,
Szeged, Hungary; ¶Department of Geriatric Medicine, Katholieke Universiteit Leuven, Leuven, Belgium; **Department
of Medicine, University of Santiago de Compostela, Santiago de Compostela, Spain; ††Scanian Andrology Centre,
Department of Urology, Malmö University Hospital, University of Lund, Lund, Sweden; ‡‡Department of Reproductive
Biology, Imperial College London, Hammersmith Campus, London, UK; §§Department of Andrology and Reproductive
Endocrinology, Medical University of Lodz, Lodz, Poland; ¶¶Department of Geriatric Medicine, University of Manchester,
Manchester, UK; ***Andrology Unit, Tartu University Hospital, Tartu, Estonia; †††The University of Manchester, Department
of Endocrinology, Manchester Royal Infirmary, Manchester, UK
DOI: 10.1111/j.1743-6109.2008.00781.x
A B S T R A C T
Introduction. Assessment of male sexual dysfunction has been the focus of substantial scientiﬁc effort. Less research
has focused on the development of instruments for the measurement of sexual functioning in aging men.
Aims. The aims of this study were: (i) to characterize the psychometric properties of a new brief, reliable, and valid
measure of male sexual functioning for use in a large population survey of middle-aged and elderly European men;
and (ii) speciﬁcally, to determine whether the new instrument, the European Male Ageing Study–sexual function
questionnaire (EMAS–SFQ), discriminates between men with high and low levels of circulating testosterone (T)
(total T, free T, and bioavailable T).
Method. One thousand six hundred men aged 40–79 years completed the self-administered EMAS–SFQ, the Beck
depression inventory, and provided a blood sample for assessment of sex hormones. Eighty-ﬁve men aged 35–74
years completed the EMAS–SFQ twice, 2 weeks apart to examine the test–retest reliability of the instrument.
Main Outcome Measures. Scores on the EMAS–SFQ in relation to age and T levels.
Results. Principal component analysis showed that the EMAS–SFQ had four distinct domains (overall sexual
functioning [OSF], masturbation, sexual functioning-related distress, and change in sexual functioning). The instru-
ment demonstrated excellent internal and test–retest reliability, as well as convergent, divergent, and discriminant
validity. Men with the lowest levels of total, free, and bioavailable T reported lower OSF scores compared to men
with the highest T levels.
Conclusions. The EMAS–SFQ is a valid and reproducible instrument, sensitive to age and T levels. It should be
suitable for the assessment of sexual health in population samples of men in epidemiological studies of aging.
1The EMAS study group: Florence (Gianni Forti, Luisa Petrone, and Antonio Cilotti); Glasgow (Mike Lean and Thang
Han); Leuven (Dirk Vanderschueren, Steven Boonen, and Herman Borghs); Lodz (Krzysztof Kula, Jolanta Slowikowska-
Hilczer, and Renata Walczak-Jedrzejowska); London (Ilpo Huhtaniemi); Malmö (Aleksander Giwercman); Manchester
(Frederick Wu, Alan Silman, Terence O’Neill, Joseph Finn, Philip Steer, Abdelouahid Tajar, David Lee, and Stephen Pye);
Santiago (Felipe Casanueva, Marta Ocampo, and Mary Lage); Szeged (George Bartfai, Imre Földesi, and Imre Fejes); Tartu
(Margus Punab and Paul Korrovitz); and Turku (Min Jiang).
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Introduction
Assessment of male sexual function has beenthe focus of substantial scientiﬁc research
over the past number of decades [1–10]. Most of
this work has concentrated on the identiﬁcation,
measurement, and treatment of erectile dysfunc-
tion [11–17]. Other research has been concerned
with assessing sexual dysfunction more generally
as a secondary aim in clinical studies of hypogo-
nadism and testosterone (T) replacement (re-
viewed in Isidori et al. [3]; Soran and Wu [5]).
These studies have used several validated instru-
ments such as the international index of erectile
function (IIEF), the brief sexual function inven-
tory (BSFI), the male sexual health questionnaire
(MSHQ), the Derogatis sexual functioning inven-
tory (DSFI), and the structured interview on
erectile dysfunction (SIEDY) [16–20]. However,
these instruments have largely focused on the
identiﬁcation of sexual functioning problems or
sexual dysfunction in speciﬁc patient groups such
as those receiving treatment for prostate cancer,
chemotherapy for lymphoproliferative disorders,
men experiencing lower urinary tract symptoms,
or men receiving phosphodiesterase-5 inhibitors
for erectile dysfunction.
There are generally two types of instruments
for assessing sexual dysfunction: structured inter-
views (SIs) and self-report questionnaires (SRQs;
for review, see Corona et al. [11]). Both usually
comprise a set of standardized, written probe ques-
tions requiring a ﬁnite number of responses,
driven by an interviewer (SIs) or by the subjects
themselves (SRQs). The latter (SRQs) allows more
time and privacy for the respondent to organize
and develop answers to sensitive questions. The
former (SIs) can help achieve a better patient–
physician relationship, and reduce the risk of
misunderstandings [11]. There are a number of
weaknesses in the instruments currently in use.
First, few of the instruments have been speciﬁcally
developed for administration in large, population-
based studies of non-patient samples; and of the
existing survey measures, none assess all of the
aspects of sexual functioning (e.g., the IIEF, BSFI,
and MSHQ [17–19] do not assess frequency of
sexual intercourse or masturbation [M]). Second,
several of the existing instruments are also rela-
tively detailed (e.g., the DSFI [20] comprises
200 items), hence not suitable for use in large
population-based studies, and none provide sum-
mary scores indicative of overall sexual functioning
(OSF) useful in analyzing multidisciplinary epide-
miological data. Third, many of the items included
in the existing measures are not appropriate for use
in elderly men from the general population as
opposed to patients seeking medical attention in
hospital clinics for sexual or genital–urinary com-
plaints. Fourth, none of the published measures
include a subjective assessment of changes in sex-
ual functioning (compared to 1 year earlier) or
incorporate an evaluation of whether men are dis-
tressed or worried by their current level of sexual
(dys)function. The latter is particularly notewor-
thy given that sexual function is an important com-
ponent of quality of life, and diminished sexual
functioning has been found to be associated with
psychological distress, marital problems, and
general ill health [21–23].
The European Male Ageing Study (EMAS) is a
multicenter population-based study of aging in
men aged 40–79 years. The central research ob-
jective of EMAS is to investigate the effects of
aging-related decline of endocrine functions (e.g.,
decrease in circulating T) on physical, psychologi-
cal, and sexual function. One of the challenges was
the development of a sexual function instrument
for use in general population samples of middle-
aged and elderly men across Europe. In this
article, we describe the development and valida-
tion of a sexual function instrument designed spe-
ciﬁcally to be used in EMAS: the EMAS–sexual
function questionnaire (EMAS–SFQ). Our spe-
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ciﬁc aims were: (i) to characterize the psychomet-
ric properties of the EMAS–SFQ; and (ii) to
determine whether the new instrument discrimi-
nates between men with high and low levels of
circulating T (total, free, and bioavailable), and is
sensitive to age.
Methods
Participants and Design
EMAS is a prospective study of male aging, funded
by the European Union 5th Framework Program,
“Quality of Life and Management of Living
Resources.”There are two phases: a cross-sectional
survey undertaken between 2003 and 2005 and a
follow-up investigation for 2007–2009. Men aged
40–79 years were recruited from population regis-
ters for participation in EMAS in eight European
centers (Florence [Italy], Leuven [Belgium],
Lodz [Poland], Malmö [Sweden], Manchester
[UK], Santiago de Compostela [Spain], Szeged
[Hungary], and Tartu [Estonia]). Stratiﬁed random
sampling was used with the aim of recruiting equal
numbers ofmen into each of four age bands (40–49,
50–59, 60–69, and 70–79 years). Participants were
invited by letter to participate in a wide range of
assessments (cf. Lee et al. [24]). They were invited
to complete an optional questionnaire on sexual
function (EMAS–SFQ). Of the 3,369 subjects
recruited to EMAS, 3,112 completed the EMAS–
SFQ. To ensure conﬁdentiality and encourage par-
ticipation, the SFQ was self-completed in private
and then placed in a sealable envelope by the par-
ticipants without scrutiny by the researchers. Par-
ticipants also completed an interviewer-assisted
questionnaire, which included the Beck depression
inventory. A morning (before 10:00 am) fasting
blood sample was obtained and serum was stored at
-80°C. From the 3,112 subjects who completed the
EMAS–SFQ, we selected a random sample of 200
subjects from each center to assess the performance
of theEMAS–SFQ (referred to as theEMAS–1,600
sample).
In addition to this sample, test–retest reliability
was assessed by recruiting a separate population
sample of middle-aged and elderly men from
Leeds, UK (referred to as the validation sample).
Eighty-ﬁve men aged between 35 years and 74
years responded to newspaper, Internet, and public
advertisements to take part in a study requiring
completion of the EMAS–SFQ twice, 2 weeks
apart to examine the test–retest reliability of the
instrument. In order to assess convergent and
divergent validity, the BSFI [18,25], the Beck
depression inventory [26], the Marlowe Crowne
social desirability scale [27], and an item assessing
satisfaction with general (nonsexual) relationship
with partner (see question 20, Appendix) were also
administered.
EMAS–SFQ
Development
A comprehensive review of the literature relating
to the assessment of sexual functioning in men was
conducted, and an expert panel evaluated existing
questionnaires. As outlined in the Introduction,
none of the existing questionnaires were con-
cerned with assessing levels of distress or worry
relating to current sexual functioning or evaluating
changes in sexual functioning. Therefore, ques-
tions relating to these domains of sexual function-
ing were added. An initial pool of 35 items was
identiﬁed measuring all aspects of sexual function-
ing (i.e., frequency of sexual behavior, sexual
desire/libido, erectile function, orgasmic function,
M, satisfaction, sexual-function-related distress
[SFD], change in sexual function [CSF]). This
initial pool of items formed the basis of a pilot
questionnaire that was distributed to a random
sample of men across each of the EMAS study
centers (n = 194). Linguistic validation of the
instrument was performed by the study centers
in each country including forward and backward
translations of the items before the pilot question-
naire was distributed. An item analysis of the initial
35 items was conducted on participant responses,
resulting in the removal of 18 items as they exhib-
ited poor psychometric properties. Following the
procedures outlined by Rust and Golombok [28],
items were excluded if they had: limited distribu-
tions (i.e., responses were heavily skewed), low face
validity (i.e., items were measuring aspects of
sexual dysfunction beyond the scope for a non-
patient population) or were considered inappro-
priate for use in elderly men from the general
population, low completion rate resulting in a
large amount of missing data, low discriminant
validity (i.e., items that were unrelated to age
and/or sex hormones), and low item–total correla-
tion coefﬁcients (i.e., items that had low correla-
tions with the rest of the scale). However, similar
to Mykletun et al. [25], one of the items from the
initial pool that assessed overall sexual satisfaction
(question 19) was not included in the principal
component analysis of the EMAS–SFQ (see the
following) because it did not measure a speciﬁc
aspect of sexual function (e.g., erection, inter-
course). Instead, it was included in the convergent
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and divergent validity analyses (described as
follows). The ﬁnal EMAS–SFQ consisted of 16
items, and assessed sexual functioning, SFD, and
change in sexual functioning compared to 1 year
earlier (see Appendix). The Appendix contains 20
items including the 16 EMAS–SFQ items plus the
single-item assessment of erectile dysfunction used
in the Massachusetts male aging study (MMAS),
two items on satisfaction, and one question relat-
ing to relationship status.
Hormone Measurements
T and sex-hormone-binding globulin (SHBG)
concentrations were measured by the Modular
E170 platform electrochemiluminescence im-
munoassays (Roche Diagnostics, Mannheim,
Germany). All hormone measurements were per-
formed in a single laboratory (General Laboratory,
Azienda Ospedaliero-Universitaria Careggi, Flor-
ence, Italy). FreeT levels were derived from totalT,
SHBG, and albumin concentrations, and bioavail-
able T was derived from total T and SHBG [29].
Within- and between-assay coefﬁcients of variation
for T were 1.05 and 3.72%, and 1.70 and
3.18% for SHBG, respectively. Detection limits
of the respective assays were 0.07 nmol/L and
0.35 nmol/L.
Statistical Analysis
Conventional psychometric analyses were con-
ducted to examine the reliability and validity of the
EMAS–SFQ. First, the factor structure of the
questionnaire was investigated, using a principal
component analysis with a varimax rotation, to
identify the underlying domains of the instrument.
Second, the internal reliability and test–retest reli-
ability of the subsequent domains were examined
using Cronbach’s alpha and intra-class correla-
tions, respectively. Third, discriminant validity
was explored by examining whether the instru-
ment could reliably distinguish between men with
low and high levels of T, and between different
characteristics of the study sample (e.g., older vs.
younger men). Thus, we compared the scores of
men with the highest and lowest levels of total T,
free T, and bioavailable T while controlling for the
effect of age using analysis of covariance (ancova).
Low hormone levels were deﬁned as values below
the 2.5th percentile, and high levels were deﬁned
as values above 97.5th percentile. In the total T
analyses, the low group had T levels less than
7.0 nmol/L, and the high group had T levels
greater than 29.50 nmol/L. In the free and bio-
available T analyses, the low groups had T levels
less than 140 pmol/L and 2.99 nmol/L, and the
high groups had T levels greater than 500 pmol/L
and 12.0 nmol/L, respectively. We also tested the
EMAS–SFQ’s ability to discriminate between
the different EMAS age bands (see the following).
The results of these analyses will allow us to deter-
mine whether the EMAS–SFQ is sensitive to the
effects of age and T levels. Finally, convergent and
divergent validity was explored to assess the degree
of correspondence with existing reliable and valid
instruments in similar (convergent) or different
(divergent) domains. In the current context, the
relationship between the EMAS–SFQ and the
BSFI for urology, the Beck depression inventory,
a measure of social desirability, satisfaction with
overall sex life, and satisfaction with general (non-
sexual) relationship with partner was examined. As
an additional test of convergent validity, the
relationship between the EMAS–SFQ and the
single-item assessment of erectile dysfunction
(presence or absence; question 10) used in the
MMAS [30] was also explored. Statistical analyses
were performed using SPSS version 13 (SPSS Inc.,
Chicago, IL, USA).
Results
Participants
The mean age of the 1,600 EMAS participants
was 59.4 (10.6 standard deviation [SD]) years with
365 (22.8%) aged 40–49 years, 462 (28.9%) aged
50–59 years, 435 (27.2%) aged 60–69 years, and
338 (21.2%) aged 70–79 years. Compared to those
recruited to EMAS but who did not participate in
this analysis, the 1,600 participants did not differ
in terms of age (t = 1.47, not signiﬁcant [ns]) or
total T levels (t = 1.67, ns). The mean age of the
validation sample of 85 men was 47.5 years (9.4
SD). The mean age of the low total T group was
62.0 years (range 42–80 years) and 56.8 years
(range 44–79 years) in the high T group. The
mean age of the low free T group was 66.2 years
(range 44–80 years) and 49.6 years (range 40–75
years) in the high T group, and the mean age of
the low bioavailable T group was 65.9 years (range
43–80 years) and 47.7 years (range 40–67 years) in
the high T group. The mean ages were signiﬁ-
cantly different between the high and low total T
(P < 0.05), free T (P < 0.001), and bioavailable T
(P < 0.001) groups. Therefore, the effect of age
was controlled in these group analyses as described
in the Statistical Analysis section.
Factor Analysis
The 16-item EMAS–SFQ had a Kaiser–Meyer–
Olkin measure of sampling adequacy of 0.87 and a
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signiﬁcant Bartlett’s test of sphericity (7800.71;
P < 0.001), indicating that this data set was appro-
priate for the application of factor analysis. There-
fore, a principal component analysis with a
varimax rotation was performed to investigate the
factor structure of the questionnaire items. As
shown in Table 1, four factors (or domains) with
eigenvalues greater than 1.0 emerged (range 1.21–
3.47) accounting for 64.7% of the variance. The
ﬁrst and second domains were clearly associated
with worry or distress related to OSF (“SFD”) and
with perceptions of change in sexual functioning
compared to 1 year earlier (“CSF”), respectively.
Domain 3 was associated with the frequency of all
aspects of sexual functioning and was labeled
“OSF.” Domain 4 comprised the single item relat-
ing to frequency of “M,” and indicated that this
domain of sexual functioning is distinct from OSF.
Domain scores were computed by summing the
scores for individual items from each factor, apart
from the single item score for M. The domain
score ranges, descriptive statistics, and intercorre-
lations are shown in Table 2, and the ﬁnal ques-
tionnaire in the Appendix. It is noteworthy that
the intercorrelations are moderate indicating that
each domain is measuring a different aspect of
sexual functioning in men. In addition, as pre-
dicted, the relationship between the OSF and SFD
domains is negative, signifying that men with
lower sexual functioning scores report higher
levels of distress or worry.
Please note that 112 men did not have a partner
in the EMAS–1,600 sample. Independent sample t
tests showed that men without partners mastur-
bated signiﬁcantly more frequently than men with
partners (t = 3.70; P < 0.01). However, the result
of the factor analysis was identical when men
without partners were excluded; therefore, these
men were retained in the analyses.
Scale Reliability
Internal consistency of the subscales was assessed
using Cronbach’s alpha, and test–retest reliability
in the validation sample was evaluated using intra-
class correlations. The alphas for the OSF, SFD,
and CSF subscales were 0.80, 0.88, and 0.86,
respectively. The intra-class correlation coefﬁ-
Table 1 Principal component analysis with a varimax rotation of the European Male Ageing Study (EMAS)–sexual
function questionnaire (SFQ): factor loadings
EMAS–SFQ items Factor 1 Factor 2 Factor 3 Factor 4
Worried or distressed by current level of sexual drive/desire? 0.84
Worried or distressed by frequency of sexual activities? 0.84
Worried or distressed by ability to have an erection? 0.83
Worried or distressed by current orgasmic experience? 0.83
Worried or distressed by frequency of morning erections? 0.68
Compared with a year ago, sexual drive/desire changed? 0.80
Compared with a year ago, frequency of sexual activities changed? 0.78
Compared with a year ago, ability to have erection changed? 0.78
Compared with a year ago, has the orgasmic enjoyment changed? 0.70
Compared with a year ago, frequency of morning erections changed? 0.68
How often do you think about sex? 0.70
How many times have you attempted sexual intercourse? 0.82
How often do you engage in kissing, fondling, petting, etc.? 0.76
How often did you have the feeling of orgasm or climax? 0.65
How frequently did you awaken with a full erection? 0.51
How often do you masturbate? 0.89
Eigenvalue 3.47 3.07 2.61 1.21
Percentage variance explained 21.66 19.19 16.29 7.55
Table 2 European Male Ageing Study–sexual function questionnaire domains: descriptive statistics and intercorrelations
Domain Score range Mean
Standard
deviation OSF M SFD CSF
OSF 0 to 33 16.51 6.92 —
M 0 to 7 1.01 1.47 0.24* —
SFD 0 to 20 2.05 3.24 -0.28* 0.03 —
CSF -10 to 10 -1.41 2.62 0.39* 0.11* 0.40* —
*P < 0.001.
OSF = overall sexual functioning; M = masturbation; SFD = sexual-function-related distress; CSF = change in sexual functioning.
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cients between scores at time 1 and time 2 were
high for the OSF (0.84), M (0.93), SFD (0.82), and
CSF (0.74) subscales.
Discriminant Validity
First, the results of the ancova showed (Table 3)
that men with low levels of total T, free T, and
bioavailable T reported signiﬁcantly lower scores
on the OSF domain compared to men with high
levels of T (P < 0.01). For the M domain, men with
low levels of free T reported signiﬁcantly lower
scores (P < 0.02) compared to men with high
levels, with a trend toward signiﬁcance in the pre-
dicted direction in total T and bioavailable T
groups. No differences were found between the
total and bioavailable T groups for scores on the
SFD or CSF domains. However, men with low
levels of free T reported signiﬁcantly greater dec-
rements in their OSF in the last year (P < 0.01)
compared to men with high levels. Thus, the
EMAS–SFQ was able to discriminate between
men with high and low levels of total T, free T,
and bioavailable T within the physiological range.
This provides evidence that the EMAS–SFQ is
sensitive to different levels of circulating T.
Second, the results for age showed a signiﬁcant
main effect on each of the EMAS–SFQ domains
(Table 4). For theOSF domain, each age group was
found to be signiﬁcantly different from each other
(P < 0.001) with the highest scores reported bymen
aged between 40 years and 49 years, and the lowest
scores reported by men aged 70–79 years. For the
Table 3 Discriminant validity of European Male Ageing Study–sexual function questionnaire in men with high and low
levels of total testosterone (T), free T, and bioavailable T
Domain
High total T Low total T
P value*Mean SD Mean SD
Total T (nmol/L) 32.62 3.29 5.56 1.41 <0.000
OSF 17.04 5.77 12.48 6.82 <0.01
M 1.24 1.77 0.60 1.07 NS
SFD 2.43 3.50 2.82 3.95 NS
CSF -1.65 2.77 -2.21 2.60 NS
High free T Low free T
Free T (pmol/L) 540.0 50.0 100.0 30.0 <0.000
OSF 20.09 5.17 11.41 7.26 <0.01
M 1.65 1.69 0.40 0.87 <0.02
SFD 1.20 2.10 2.75 3.69 NS
CSF -0.46 1.69 -2.35 2.70 <0.01
High bioavailable T Low bioavailable T
Bio T (nmol/L) 13.09 1.02 1.73 0.99 <0.000
OSF 21.04 4.69 12.13 7.43 <0.01
M 1.76 1.73 0.62 1.04 <0.07
SFD 1.43 2.10 2.33 3.37 NS
CSF -0.36 1.78 -2.02 2.60 NS
*Group differences assessed using analysis of covariance controlling for age.
SD = standard deviation; OSF = overall sexual functioning; M = masturbation; SFD = sexual-function-related distress; CSF = change in sexual functioning.
Table 4 Discriminant validity and descriptive statistics for European Male Ageing Study (EMAS)–sexual function
questionnaire across age bands (EMAS subjects, n = 1,600)
Age bands (years)
EMAS age bands
OSF* M† SFD‡ CSF§
Mean SD Mean SD Mean SD Mean SD
40–49 20.42 4.83 1.44 1.70 1.27 2.32 -0.40 1.71
50–59 18.40 5.51 1.15 1.51 2.23 3.31 -1.23 2.22
60–69 14.57 6.79 0.83 1.33 2.55 3.71 -1.96 2.85
70+ 10.34 6.77 0.55 1.12 2.07 3.30 -2.30 3.32
*All age bands significantly different from each other.
†All age bands significantly different from each other except 60–69 years and 70+ years.
‡The 40–49 years band significantly different from all other.
§The 40–49 and 50–59 years age bands significantly different from all other bands and each other. The 60–69 years and 70+ years are not significantly different.
OSF = overall sexual functioning; M = masturbation; SFD = sexual-function-related distress; CSF = change in sexual functioning; SD = standard deviation.
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M domain, again each age group scored signiﬁ-
cantly differently from each other with the excep-
tion of the 60–69 years group and the 70 and over
group (P < 0.001) such that men in the younger age
groups reported a greater frequency of M com-
pared to men in the older groups. For the SFD
domain, men aged 40–49 years reported signiﬁ-
cantly lower levels of distress compared to the other
age bands (P < 0.001). However, no other differ-
ences were observed between the groups. Finally,
men aged 40–49 and 50–59 years reported signiﬁ-
cantly lower decreases in OSF within the last year
compared to men aged 60–69 and 70+ years. Taken
together, these ﬁndings indicate the EMAS–SFQ
possesses good discriminant validity, it is sensitive
to age, and it is able to reliably distinguish between
high and low levels of circulating T.
Convergent and Divergent Validity
Table 5 shows the pattern of correlations and indi-
cates, as predicted, that the EMAS–SFQ domain
coefﬁcients are generally higher with conceptually
similar constructs (e.g., BSFI), and lower with con-
ceptually dissimilar constructs (e.g., depression,
social desirability, satisfaction with general [non-
sexual] relationship). In addition, the (point bise-
rial) correlation coefﬁcients show that the
presence of erectile dysfunction is signiﬁcantly
associated with lower OSF and M scores, and
higher levels of SFD and greater negative changes
in sexual functioning within the last year.
Discussion
The EMAS–SFQ is a 16-item self-administered
questionnaire designed to provide a single-score
assessment of OSF together with a measure of
SFD and an evaluation of changes in sexual func-
tioning compared to a year ago. The results of
the principal component analysis showed that
the EMAS–SFQ has four distinct domains. Two
domains are concerned with sexual functioning
(OSF and M), one with SFD, and one with CSF. It
is noteworthy that M is separate from OSF sug-
gesting that it should be considered as a separate
entity in the global, overall assessment of sexual
health. However, it is an important aspect that is
frequently not included in measures of male sexual
functioning. As a result, less is known about age-
related changes in M or the role of T deﬁciency
in this aspect of male sexual behavior. Indeed, to
this end, Corona et al. have recently developed
ANDROTEST, an SI for the screening of hypo-
gonadism in patients with sexual dysfunction,
which includes two items relating to M [31].
The psychometric properties of the EMAS–
SFQ were found to be excellent, and show that the
single score for OSF provides a good indicator of
global functioning. Moreover, the OSF score was
found to be signiﬁcantly associated with the well-
validated measure of erectile dysfunction from the
MMAS [30] and with the single-item measure of
satisfaction with overall sex life. This is important
for two reasons. First, these ﬁndings indicate that
the OSF score has good convergent validity.
Second, they highlight the need for future re-
search on overall sexual health in aging men to
include not only the 16-item EMAS–SFQ, but also
these additional, brief measures of erectile dys-
function and sex life satisfaction.
The EMAS–SFQ was also found to demon-
strate good reliability and validity in a large sample
Table 5 Convergent and divergent validity: correlations (r) with other related and unrelated variables
Variable
EMAS–SFQ domains
OSF M SFD CSF
r R r R
BSFI domains†
Sexual drive 0.44*** 0.32** -0.49*** -0.09
Erection 0.55*** 0.32** -0.73*** -0.39***
Ejaculation 0.44*** 0.31** 0.71*** -0.04
Problem assessment 0.47*** 0.28* 0.80*** -0.32**
Social desirability scale† -0.11 0.05 0.01 0.01
Beck depression inventory‡ 0.33*** -0.09** 0.30*** -0.25***
Satisfaction with sex life‡ 0.31*** -0.08** -0.42*** 0.29***
Erectile dysfunction‡§ -0.56*** -0.09** 0.43*** -0.41***
Satisfaction with general relationship 0.10** -0.02 -0.11*** 0.07*
*P < 0.05; **P < 0.01; ***P < 0.001.
†Coefficients obtained from validation sample.
‡Coefficients obtained from EMAS.
§Point biserial correlation coefficients (0 absence, 1 presence of erectile dysfunction).
Data from validation sample (n = 85) and EMAS (n = 1,600).
EMAS–SFQ = European Male Ageing Study–sexual function questionnaire; OSF = overall sexual functioning; M = masturbation; SFD = sexual-function-related
distress; CSF = change in sexual functioning.
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of European men aged 40–79 years. In the current
analyses, psychometric validation was addressed in
four main areas: (i) internal reliability; (ii) test–
retest reliability; (iii) convergent and divergent
validity; and (iv) discriminant validity. The perfor-
mance of the EMAS–SFQ in each of these areas
was shown to be excellent, and as such this new
measure is appropriate for use in epidemiologi-
cal research in populations of aging men from
the community (cf. Rust and Golombok [28];
O’Connor et al. [32]; Rosen et al. [17]). Of par-
ticular note are the ﬁndings relating to the dis-
criminant validity of the measure. The instrument
was found to be sensitive to different age bands
with the highest scores observed in the youngest
age group, as well as being able to distinguish
between men with low and high levels of circulat-
ing T. The OSF domain score was found to exhibit
a linear relationship with age such that scores
between each of the 10-year age bands were found
to be signiﬁcantly different from each other. This
is a further demonstration of the suitability of this
new measure for use in large, community-based
prospective studies such as the EMAS.
The age-related ﬁndings for SFD are interest-
ing and require further comment. The results
indicated that the levels of distress or worry
reported by men in each age band were relatively
low (range 1.27–2.55; maximum scale score = 20)
with the lowest scores observed in the youngest
age group. This is not surprising given that
the EMAS–SFQ is primarily aimed at assessing
normal age-related sexual function (rather than
dysfunction), and men aged 40–49 years are likely
to be content with their OSF. In addition, the
pattern of ﬁndings suggests that the relationship
between age and SFD may not be linear such that
men aged 50 years or over do not experience incre-
mental increases in distress even though there is
progressive decline in sexual function.
Finally, this article also aimed to examine
whether this new instrument could distinguish
between men with high and low levels of circulat-
ing T in a physiologically meaningful manner. We
found that the EMAS–SFQ was able to reliably
discriminate between individuals with low and
high total, free, and bioavailable T levels in the
anticipated direction. In particular, for all three
measures of circulating T, men with the lowest
levels exhibited signiﬁcantly lower OSF scores
compared to men with the highest levels.
However, few T-related differences were found
between the groups for SFD and CSF. The latter
ﬁnding may indicate that circulating T levels are
less important than other factors such as age, for
the maintenance of these aspects of sexual func-
tioning in middle-aged and elderly men. It is also
possible that low levels of T are not related to
CSFs or distress because basal levels of sexual
behavior may have stabilized previously over
several years.
In conclusion, the EMAS–SFQ is a valid, repro-
ducible instrument for the assessment of sexual
health in population samples of European men and
should be considered as an important new instru-
ment speciﬁcally developed for epidemiological
studies of aging in the male population.
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Appendix
EMAS Sexual Function Questionnaire (EMAS–SFQ)
Please circle the one response that best describes you IN THE LAST MONTH.
1. Please tick one statement that best describes your circumstances.
1. I have been living with my wife.
2. I have been living with my partner.
3. I have a sexual partner but we did not live together.
4. I do not have a sexual partner.
2. How often did you think about sex? This includes times of just being interested in sex, daydreaming,
or fantasizing about sex, as well as times when you wanted to have sex.
0. Not at all
1. Once in the last month
2. 2–3 times in the last month
3. Once a week
4. 2–3 times a week
5. 4–6 times a week
6. Once a day
7. More than once a day
3. Are you worried or distressed by your current level of sexual drive/desire?
0. Not at all worried or distressed
1. A little bit worried or distressed
2. Moderately worried or distressed
3. Very worried or distressed
4. Extremely worried or distressed
4. Compared with a year ago, has your sexual drive/desire changed?
+2. Increased a lot
+1. Increased moderately
0. Neither increased nor decreased
-1. Decreased moderately
-2. Decreased a lot
If you did NOT have a sexual partner in the LAST MONTH, please skip questions 5 and 6 and go
straight to question 7.
5. How many times have you attempted sexual intercourse?
0. Not at all
1. Once in the last month
2. 2–3 times in the last month
3. Once a week
4. 2–3 times a week
5. 4–6 times a week
6. Once a day
7. More than once a day
6. Apart from when you attempted sexual intercourse, how frequently did you engage in activities such
as kissing, fondling, petting, etc.?
0. Not at all
1. Once in the last month
2. 2–3 times in the last month
3. Once a week
4. 2–3 times a week
5. 4–6 times a week
6. Once a day
7. More than once a day
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7. How often did you masturbate?
0. Not at all
1. Once in the last month
2. 2–3 times in the last month
3. Once a week
4. 2–3 times a week
5. 4–6 times a week
6. Once a day
7. More than once a day
8. Are you worried or distressed by the overall frequency of your sexual activities (including inter-
course, kissing, etc., and masturbation)?
0. Not at all worried or distressed Skip question 8A and go straight to question 9
1. A little bit worried or distressed
2. Moderately worried or distressed
3. Very worried or distressed
4. Extremely worried or distressed
8A. If you are worried or distressed by the current frequency of your sexual activities, do
you consider it to be
1. Too frequent
2. Not frequent enough
9. Compared with a year ago, has the overall frequency of your sexual activities changed?
+2. Increased a lot
+1. Increased moderately
0. Neither increased nor decreased
-1. Decreased moderately
-2. Decreased a lot
It is common for men to experience erectile problems. This may mean that one is not always able to get
or keep an erection that is rigid enough for satisfactory activity (including sexual intercourse and
masturbation). In the LAST MONTH:
10. You are
1. Always able to keep an erection which would be good enough for sexual intercourse
2. Usually able to get and keep an erection which would be good enough for sexual intercourse
3. Sometimes able to get and keep an erection which would be good enough for sexual intercourse
4. Never able to get and keep an erection which would be good enough for sexual intercourse
11. Are you worried or distressed by your current ability to have an erection?
0. Not at all worried or distressed
1. A little bit worried or distressed
2. Moderately worried or distressed
3. Very worried or distressed
4. Extremely worried or distressed
12. Compared with a year ago, has your ability to have an erection changed?
+2. Increased a lot
+1. Increased moderately
0. Neither increased nor decreased
-1. Decreased moderately
-2. Decreased a lot
13. When you had sexual stimulation, how often did you have the feeling of orgasm or climax?
0. No sexual intercourse/masturbation
1. Almost never/never
2. A few times (much less than half the time)
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3. Sometimes (about half the time)
4. Most of the time (much more than half the time)
5. Almost always/always
14. Are you worried or distressed by your current orgasmic experience?
0. Not at all worried or distressed
1. A little bit worried or distressed
2. Moderately worried or distressed
3. Very worried or distressed
4. Extremely worried or distressed
15. Compared with a year ago, has the enjoyment of your orgasmic experience changed?
+2. Increased a lot
+1. Increased moderately
0. Neither increased nor decreased
-1. Decreased moderately
-2. Decreased a lot
16. How frequently did you awaken with full erection?
0. Not at all
1. Once in the last month
2. 2–3 times in the last month
3. Once a week
4. 2–3 times a week
5. 4–6 times a week
6. Once a day
7. More than once a day
17. Are you worried or distressed by the frequency of your morning erections?
0. Not at all worried or distressed
1. A little bit worried or distressed
2. Moderately worried or distressed
3. Very worried or distressed
4. Extremely worried or distressed
18. Compared with a year ago, has the frequency of your morning erections changed?
+2. Increased a lot
+1. Increased moderately
0. Neither increased nor decreased
-1. Decreased moderately
-2. Decreased a lot
19. How satisﬁed have you been with your overall sex life?
0. Very dissatisﬁed
1. Moderately dissatisﬁed
2. About equally satisﬁed and dissatisﬁed
3. Moderately satisﬁed
4. Very satisﬁed
20. How satisﬁed have you been with your general (nonsexual) relationship with your partner?
1. Very dissatisﬁed
2. Moderately dissatisﬁed
3. About equally satisﬁed and dissatisﬁed
4. Moderately satisﬁed
5. Very satisﬁed
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